Drug Patents owned by Mallinckrodt Hosp
1. List of Inomax drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8846112 | MALLINCKRODT HOSP | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation |
Jun, 2029
(6 years from now) | |
| US8282966 | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide |
Jun, 2029
(6 years from now) | |
| US8293284 | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide |
Jun, 2029
(6 years from now) | |
| US8795741 | MALLINCKRODT HOSP | Methods for treating patients who are candidates for inhaled nitric oxide treatment |
Jun, 2029
(6 years from now) | |
| US8431163 | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas |
Jun, 2029
(6 years from now) | |
|
US8431163
(Pediatric) | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas |
Dec, 2029
(6 years from now) | |
|
US8282966
(Pediatric) | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide |
Dec, 2029
(6 years from now) | |
|
US8293284
(Pediatric) | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide |
Dec, 2029
(6 years from now) | |
|
US8795741
(Pediatric) | MALLINCKRODT HOSP | Methods for treating patients who are candidates for inhaled nitric oxide treatment |
Dec, 2029
(6 years from now) | |
|
US8846112
(Pediatric) | MALLINCKRODT HOSP | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation |
Dec, 2029
(6 years from now) | |
| US9265911 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(7 years from now) | |
| US9408993 | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jan, 2031
(7 years from now) | |
| US8776794 | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jan, 2031
(7 years from now) | |
| US8776795 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(7 years from now) | |
| US8291904 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(7 years from now) | |
| US9295802 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(7 years from now) | |
| US8573210 | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jan, 2031
(7 years from now) | |
| US8573209 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(7 years from now) | |
|
US8573209
(Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(8 years from now) | |
|
US8573210
(Pediatric) | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jul, 2031
(8 years from now) | |
|
US9295802
(Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(8 years from now) | |
|
US9408993
(Pediatric) | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jul, 2031
(8 years from now) | |
|
US9265911
(Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(8 years from now) | |
|
US8291904
(Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(8 years from now) | |
|
US8776795
(Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(8 years from now) | |
|
US8776794
(Pediatric) | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jul, 2031
(8 years from now) | |
| US9279794 | MALLINCKRODT HOSP | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide |
Feb, 2034
(11 years from now) | |
|
US9279794
(Pediatric) | MALLINCKRODT HOSP | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide |
Aug, 2034
(11 years from now) | |
| US9770570 | MALLINCKRODT HOSP | Apparatus and method for monitoring nitric oxide delivery |
May, 2036
(13 years from now) | |
|
US9770570
(Pediatric) | MALLINCKRODT HOSP | Apparatus and method for monitoring nitric oxide delivery |
Nov, 2036
(13 years from now) | |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 23 December, 1999
Treatment: A method of reducing the risk of pulmonary edema in patients in need of treatment with inhaled nitric oxide; A method of providing nitric oxide therapy to a patient by verifying gas information of nitric oxide prior to delivery to patient; A method of providing a predetermined concentration of nitric oxide to a patient; A method of treating hypoxic respiratory failure by verifying gas information of nitric oxide prior to delivery to patient; A method of providing nitric oxide therapy to a patient by compensating long-term sensitivity drift of electrochemical gas sensors used in systems for delivering therapeutic nitric oxide to a patient; A method of providing nitric oxide therapy to a patient by measuring and displaying an indication of the calculated delivery concentration of nitiric oxide as compared to the desired delivery concentration of nitric oxide
Dosage: GAS;INHALATION
2. List of Ofirmev drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9610265 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Nov, 2028
(5 years from now) | |
| US10383834 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Nov, 2028
(5 years from now) | |
| US9987238 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Nov, 2028
(5 years from now) | |
|
US9987238
(Pediatric) | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
May, 2029
(6 years from now) | |
|
US9610265
(Pediatric) | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
May, 2029
(6 years from now) | |
| US9399012 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Sep, 2031
(8 years from now) | |
|
US9399012
(Pediatric) | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Mar, 2032
(9 years from now) | |
Drugs and Companies using ACETAMINOPHEN ingredient
Market Authorisation Date: 02 November, 2010
Treatment: Modified dosing regimen for the management of moderate to severe pain with adjunctive opioid analgesics; Modified dosing regimen for the reduction of fever; Modified dosing regimen for the management of mild to moderate pain; Modified dosing regimen for the management of mild to moderate pain or management of moderate to severe pain as an adjunct to opioid analgesics
Dosage: SOLUTION;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic